By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


DelMar Pharmaceuticals 

999 West Broadway
Suite 720
  British Columbia  V5Z 1K5  Canada
Phone: 1-604-629-5989 Fax:



Company News
DelMar Pharma Receives Institutional Review Board Approval For Pivotal Phase III Clinical Trial Of VAL-083 In Refractory GBM 6/22/2017 7:26:49 AM
DelMar Pharma Presents Poster Of Clinical Research With VAL-083 In Patients With Chemo-Resistant Glioblastoma ("GBM") At SNO's Pediatric Neuro-Oncology Basic And Translational Research Conference 6/16/2017 6:45:28 AM
DelMar Pharma Announces Third Quarter Fiscal Year 2017 Financial Results 5/19/2017 8:45:47 AM
DelMar Pharma Formalizes Collaboration With PRA Health Sciences For Phase III Trial Of VAL-083 In Recurrent Glioblastoma Multiforme (GBM) 5/11/2017 7:41:21 AM
DelMar Pharma Presents New Mechanism Of Action Data For Its Lead Agent VAL-083 In Temozolomide-Resistant Glioblastoma Multiforme (GBM) At The World Federation Of Neuro-Oncology Societies (WFNOS) 5/8/2017 7:34:39 AM
DelMar Pharma Collaborates With Duke University To Explore VAL-083 As A Front-Line Treatment For Glioblastoma Multiforme 4/25/2017 7:26:37 AM
DelMar Pharma Announces Closing Of $9,000,000 Public Offering Of Common Stock And Warrants 4/21/2017 7:21:08 AM
DelMar Pharma Announces Pricing Of $9,000,000 Public Offering Of Common Stock And Warrants 4/13/2017 11:03:52 AM
DelMar Pharma Provides VAL-083 Updates From The Ongoing AACR Annual Meeting 4/5/2017 7:54:35 AM
DelMar Pharma Announces Second Quarter Fiscal Year 2017 Financial Results 2/13/2017 8:30:53 AM